-
In a prospective trial conducted from 2004-2010, 21 patients (median age 65 years) with a clinical complete response after chemoradiotherapy were followed closely per a stringent wait-and-see policy consisting of MRI, endosopies, and CT scans. These patients were compared to 20 patients prospectively who underwent surgery and were found to have a pathologic complete response.
-
-
This randomized, controlled, open-label, multicenter Phase 3 trial compared axitinib with sorafenib as second-line therapy for metastatic renal clear-cell cancer. The results showed that axitinib extended progression-free survival by 2 months more than sorafenib (6.7 months vs 4.7 months), and had a superior objective response rate (19.4% vs 9.4%).
-
-
There is perhaps no greater public health passion than that for fighting cancer. There is also perhaps no greater confusion than that surrounding nutrition and cancer. Public "cancer scares" regarding environmental exposures and alternative treatments often capture the public's attention.
-
An asymptomatic 78-year-old retired accountant presented to his physician with intractable hiccups. Physical examination, complete blood count, and imaging studies did not reveal a cause of the hiccups, and after several days the symptom disappeared. However, upon review of the abdominal CT scan obtained in evaluation of the hiccups, a right renal mass was defined.
-
New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
-
I previously shared some thoughts on communication styles and keeping a log of questions along with your answers that come through your Infection Prevention & Control (IP&C) Program.
-
-
State health departments are becoming vital partners with the Centers for Disease Control and Prevention in an increasing national effort to eradicate healthcare associated infections (HAIs).